In the FOURIER and ODYSSEY trials, women comprised about 25% of participants, but they experienced similar reductions in LDL and major adverse cardiovascular events as men when treated with PCSK9 inhibitors.

“unfortunately both of these trials women were only about 25 percent of participants you know women start out with higher ldls for various reasons you know after menopause women tend to have higher ldls compared to men but that they had a similar reduction in LDL with pcsq9 inhibitor therapy in terms of Mace reduction there was no interaction by sex meaning that women benefited these high-risk women who either have ascvd or recent acute coronary syndrome benefited to a similar degree as men did”